Shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.76 and traded as low as $0.67. Protagenic Therapeutics shares last traded at $0.68, with a volume of 18,049 shares traded.
Protagenic Therapeutics Price Performance
The business's 50 day moving average price is $0.66 and its 200 day moving average price is $0.76. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.47 and a current ratio of 19.47.Get Protagenic Therapeutics alerts:
Institutional Trading of Protagenic Therapeutics
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC raised its stake in shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned approximately 0.59% of Protagenic Therapeutics worth $83,000 as of its most recent SEC filing. 3.50% of the stock is currently owned by institutional investors.
Protagenic Therapeutics Company Profile(Get Rating)
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.